These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 15650449

  • 1. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
    Dillman R, Barth N, Vandermolen L, Mahdavi K, Beutel L, de Leon C, DePriest C, Nayak S.
    Cancer Biother Radiopharm; 2004 Oct; 19(5):570-80. PubMed ID: 15650449
    [Abstract] [Full Text] [Related]

  • 2. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO, Barth NM, VanderMolen LA, Garfield DH, De Leon C, O'Connor AA, Mahdavi K, Nayak SK.
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [Abstract] [Full Text] [Related]

  • 3. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas.
    Dillman R, Barth N, Selvan S, Beutel L, de Leon C, DePriest C, Peterson C, Nayak S.
    Cancer Biother Radiopharm; 2004 Oct; 19(5):581-8. PubMed ID: 15650450
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.
    Dillman RO, Nayak SK, Barth NM, DeLeon C, Schwartzberg LS, Spitler LE, Church C, O'Connor AA, Beutel LD.
    Cancer Biother Radiopharm; 1998 Jun; 13(3):165-76. PubMed ID: 10850352
    [Abstract] [Full Text] [Related]

  • 8. Cancer vaccine potency: is there a dose/response relationship for patient-specific vaccines and clinical outcomes?
    Dillman RO, Beutel L, Nayak S, Depriest C, Selvan S, Schiltz P.
    Cancer Biother Radiopharm; 2005 Aug; 20(4):373-8. PubMed ID: 16114985
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW, Han H, Li YQ, Chen SP, Xia JC.
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [Abstract] [Full Text] [Related]

  • 10. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ.
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [Abstract] [Full Text] [Related]

  • 11. Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer.
    Dillman RO, Beutel LD, Cornforth AN, Nayak SK.
    Cancer Biother Radiopharm; 2000 Apr; 15(2):161-8. PubMed ID: 10803321
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
    Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M, Sacco C, Talamini R.
    Cancer; 1996 Jun 15; 77(12):2560-6. PubMed ID: 8640706
    [Abstract] [Full Text] [Related]

  • 14. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
    Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hübinger AM, Müller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG.
    Hum Gene Ther; 2003 Mar 20; 14(5):483-94. PubMed ID: 12691613
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.
    J Urol; 2001 Jul 20; 166(1):68-72. PubMed ID: 11435825
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects.
    Adler A, Gillon G, Lurie H, Shaham J, Loven D, Shachter Y, Shani A, Servadio C, Stein JA.
    J Biol Response Mod; 1987 Dec 20; 6(6):610-24. PubMed ID: 3330126
    [Abstract] [Full Text] [Related]

  • 19. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma.
    Dillman RO, DeLeon C, Beutel LD, Barth NM, Schwartzberg LS, Spitler LE, Garfield DH, O'Connor AA, Nayak SK.
    Crit Rev Oncol Hematol; 2001 Dec 20; 39(1-2):115-23. PubMed ID: 11418308
    [Abstract] [Full Text] [Related]

  • 20. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
    Berd D, Maguire HC, McCue P, Mastrangelo MJ.
    J Clin Oncol; 1990 Nov 20; 8(11):1858-67. PubMed ID: 2230873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.